Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its mid-stage study for the treatment of Duchenne muscular dystrophy.
Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its mid-stage study for the treatment of Duchenne muscular dystrophy.